Legend Biotech Corporation
LEGN
$34.86
$1.374.09%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.45% | 12.55% | |||
| Total Other Revenue | -- | -716.67% | |||
| Total Revenue | -0.42% | 12.50% | |||
| Cost of Revenue | 16.38% | -1.61% | |||
| Gross Profit | -46.69% | 85.96% | |||
| SG&A Expenses | -10.96% | 15.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 220.00% | -- | |||
| Total Operating Expenses | 8.54% | 3.55% | |||
| Operating Income | -141.72% | 52.59% | |||
| Income Before Tax | -170.93% | 49.84% | |||
| Income Tax Expenses | -89.30% | 1,720.78% | |||
| Earnings from Continuing Operations | -76.21% | 22.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -76.21% | 22.36% | |||
| EBIT | -141.72% | 52.59% | |||
| EBITDA | -164.58% | 56.87% | |||
| EPS Basic | -75.90% | 22.42% | |||
| Normalized Basic EPS | -157.61% | 47.39% | |||
| EPS Diluted | -66.02% | 17.86% | |||
| Normalized Diluted EPS | -157.61% | 47.39% | |||
| Average Basic Shares Outstanding | 0.20% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||